title: Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease.
abstract: This study assessed the effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand after percutaneous coronary intervention in patients who had stable coronary artery disease. Tirofiban insignificantly limited the increase of soluble CD40 ligand after revascularization, especially in patients who had high levels of this marker at baseline (p = 0.06), whereas statins significantly inhibited increases in interleukin-6 and, to a lesser extent, high-sensitivity C-reactive protein without affecting the soluble CD40 ligand.
authors.affiliation: Division of Cardiology, Hotel Dieu de France Hospital, St. Joseph University School of Medicine, Achrafieh, Beirut, Lebanon. razar@usj.edu.lb
authors.forename: Rabih R
authors.initials: RR
authors.lastname: Azar
authors.forename: Georges
authors.initials: G
authors.lastname: Badaoui
authors.forename: Antoine
authors.initials: A
authors.lastname: Sarkis
authors.forename: Roland
authors.initials: R
authors.lastname: Kassab
authors.forename: Elie
authors.initials: E
authors.lastname: Salamé
authors.forename: Samira
authors.initials: S
authors.lastname: Klaymé
authors.forename: Roger
authors.initials: R
authors.lastname: Naman
authors.forename: Mirna
authors.initials: M
authors.lastname: Germanos
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D002097:C-Reactive Protein / Q000378:metabolism; D023201:CD40 Ligand / Q000097:blood; D003324:Coronary Artery Disease / Q000097:blood / Q000628:therapy; D023903:Coronary Restenosis / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D007262:Infusions, Intravenous; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D011446:Prospective Studies; D000077466:Tirofiban; D016896:Treatment Outcome; D014443:Tyrosine / Q000008:administration & dosage* / Q000031:analogs & derivatives*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D015850:Interleukin-6; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D023201:CD40 Ligand; D014443:Tyrosine; D002097:C-Reactive Protein; D000077466:Tirofiban